💉 GLP-1RA stop risk 41% at 1 year in UK T2D

In a UK primary care cohort of 8,200 adults with type 2 diabetes starting a GLP-1 receptor agonist, the 1-year discontinuation risk was 41.1% (95% CI 40.1–42.2), with higher stopping in patients without obesity and the lowest discontinuation on dulaglutide. The analysis used IQVIA Medical Research Data (IMRD) incorporating THIN (A Cegedim Database) from 2018–2023.

Why It Matters To Your Practice

• Nearly 2 in 5 patients stopped GLP-1RA therapy within a year (41.1%), signaling that “trial-like” persistence may not reflect real-world primary care.

• Stopping was higher without obesity (BMI <30: 49.2%) vs with obesity (BMI ≥30: ~37.2%–40.4%), which can inform adherence counseling and follow-up intensity.

• Discontinuation patterns were similar across patient subgroups, including those with established cardiovascular disease (Heart disease), suggesting persistence challenges are broadly distributed.

Clinical Benefits

• Agent choice mattered: 1-year discontinuation was lower with dulaglutide (36.9%) than with subcutaneous semaglutide (46.4%) or oral semaglutide (55.8%).

• Dose trajectories showed many patients do not reach recommended maintenance doses on time—important when assessing “nonresponse” vs underdosing.

• By prescription 10, common stable doses clustered at typical maintenance ranges (e.g., SC semaglutide 0.5/1 mg; oral semaglutide 7/14 mg; dulaglutide 1.5 mg), which can help benchmark where your panel tends to land.

Managing Risks

• Plan for early follow-up: only 58% of semaglutide initiators reached recommended maintenance doses after 4 weeks, while 21% remained on starting doses—raising the risk of persistent GI effects, slow benefit accrual, and frustration-driven discontinuation.

• Build a titration workflow (scheduled check-ins, symptom-guided adjustments, refill timing) to reduce “stalling” at starter doses and unintentional gaps.

• When patients consider stopping, reassess drivers (tolerability, access/cost, injection technique, expectations) and document a re-challenge or alternative GLP-1RA plan when appropriate.

The Bottom Line

• In UK primary care, GLP-1RA persistence was suboptimal: 41.1% stopped within 1 year.

• Discontinuation was higher in patients without obesity and lowest with dulaglutide; semaglutide titration commonly lagged.

• For NPs/PAs, proactive titration support and early troubleshooting may be as important as initial agent selection for keeping patients on therapy long enough to benefit.